Core Viewpoint - China Resources Pharmaceutical (03320) reported a decline in revenue and net profit for Kunming Pharmaceutical Group for the nine months ending September 30, 2025, indicating challenges in the company's financial performance [1] Financial Performance - Total revenue for the period was 4.751 billion RMB, representing a year-on-year decrease of 18.08% [1] - Net profit for the same period was 323 million RMB, reflecting a year-on-year decline of 35.76% [1]

证券代码：600422 证券简称：昆药集团 公告编号：2025-053 号 昆药集团股份有限公司关于对外担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 担保对象一 | 被担保人名称 | | 云南省丽江医药有限公司（以下简称"丽江医药"） | | --- | --- | --- | --- | | | 本次担保金额 | 720 万元 | | | | 实际为其提供的担保余额 | 万元 720 | | | | 是否在前期预计额度内 | □否 是 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | 不适用：_________ | | 担保对象二 | 被担保人名称 | | 红河州佳宇药业有限公司（以下简称"红河佳宇"） | | | 本次担保金额 | 万元 900 | | | | 实际为其提供的担保余额 | 900 万元 | | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | □不适用：____ ...

1、 关于公司 2025 年第三季度报告的议案（公司 2025 年第三季度报告刊登于上海证 券交易所网站 www.sse.com.cn） 同意：5 票 反对：0 票 弃权：0 票 监事会书面审核意见： 证券代码：600422 证券简称：昆药集团 公告编号：2025-052号 昆药集团股份有限公司十一届七次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 10 月 24 日 以通讯表决方式召开公司十一届七次监事会会议。会议通知以书面方式于 2025 年 10 月 17 日发出。会议由公司监事会主席钟江先生召集并主持，本次会议应参加表决监 事 5 人，实际参加表决 5 人，符合《公司法》和《公司章程》的规定。会议审议并通 过了以下决议： 同意：5 票 反对：0 票 弃权：0 票 特此公告。 昆药集团股份有限公司监事会 2025 年 10 月 25 日 1 公司第三季度报告的编制和审议程序符合法律、法规、公司章程和公司内部管理 制度的各项规定；公司 ...

昆药集团股份有限公司十一届九次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 10 月 24 日以通讯表决方式召开公司十一届九次董事会会议。会议通知以书面方式于 2025 年 10 月 17 日发出。会议由公司董事长吴文多先生召集并主持，本次会议应参加表决董 事 9 人，实际参加表决 9 人，符合《公司法》和《公司章程》的规定。会议以记名方 式投票表决，审议并通过以下决议： 1、 关于公司 2025 年第三季度报告的议案（公司 2025 年第三季度报告刊登于上海证 券交易所网站 www.sse.com.cn） 证券代码：600422 证券简称：昆药集团 公告编号：2025-051号 同意：9 票 反对：0 票 弃权：0 票 3、 关于制订公司《市值管理制度》的议案 为进一步加强与规范公司的市值管理活动，维护公司、投资者及其他利益相关者 的合法权益，根据有关法律、法规和规定，结合公司实际，制订公司《市值管理制度》。 1 同意：9 票 反对：0 ...

昆药集团股份有限公司 2025 年第三季度报告 证券代码：600422 证券简称：昆药集团 昆药集团股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人颜炜、主管会计工作负责人孙志强及会计机构负责人（会计主管人员）杨学炳保证季 度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | | 本报告期 比上年同 | | | | 年初至报 告期末比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期增减变 | 年初至报告期末 | 上年同期 | | 上年同期 | | | | | | 动幅度(%) | | | ...

Core Insights - The company reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year [1] Financial Performance - Third quarter revenue was 1.4 billion, a year-on-year decrease of 30.19% [1] - Third quarter net profit was 71.01 million, a year-on-year decrease of 59.03% [1] - Revenue for the first three quarters was 4.751 billion, a year-on-year decrease of 18.08% [1] - Net profit for the first three quarters was 269 million, a year-on-year decrease of 39.42% [1]

近日，深圳市地方金融管理局、深圳市发展和改革委员会、深圳市科技创新局等六部门联合印发《深圳 市推动并购重组高质量发展行动方案（2025—2027年）》（以下简称《行动方案》）。 《行动方案》提出，围绕深圳"20+8"产业战略要求，进一步强化资本市场与产业优势，重点支持符合国 家战略、突破关键核心技术、契合新质生产力发展导向的企业开展并购重组，推动产业经营与资本运营 深度融合发展，培育具有全球竞争力的世界一流企业和行业领军企业，提升深圳市产业链活力与韧性。 并购重组"向新" 一直以来，并购重组是上市公司和产业企业优化资源配置、推动产业升级、提升经营效益的重要手段。 2024年以来，并购重组政策出台进一步提速。《国务院关于加强监管防范风险推动资本市场高质量发展 的若干意见》（即新"国九条"）、《关于深化上市公司并购重组市场改革的意见》（以下简称"并购六 条"）、修订后的《上市公司重大资产重组管理办法》（以下简称"重组新规"）的相继推出，为并购重 组市场改革进一步深化提供了政策支撑。 根据《行动方案》，此次深圳推动并购重组高质量发展的重点任务包括：聚焦新质生产力开展并购重 组；建立上市公司并购重组标的项目库；丰富拓 ...

Core Points - The Shenzhen Municipal Financial Management Bureau and other departments have launched an action plan to promote high-quality development through mergers and acquisitions (M&A) for local listed companies from 2025 to 2027, aiming for a total market value of over 20 trillion yuan and the cultivation of 20 companies with a market value of over 100 billion yuan by the end of 2027 [1][2] Group 1: Focus on New Quality Productivity - The action plan emphasizes the integration of M&A with Shenzhen's "20+8" strategic emerging industry clusters, supporting leading companies in sectors like integrated circuits, artificial intelligence, new energy, and biomedicine to enhance their supply chains through acquisitions [2] - The plan aims to replicate successful M&A models seen in tech giants like Amazon and Nvidia, which have achieved growth through continuous integration and technology upgrades [2] - Successful cases such as BYD's acquisition of Jabil's mobile electronics business and Luxshare Precision's acquisition of Qorvo's semiconductor assets illustrate the value of M&A in expanding customer boundaries and deepening industry integration [2] Group 2: Building a Patient Capital System - To address funding challenges for M&A, the plan proposes a comprehensive financial support system, encouraging the use of various financing tools such as cash, shares, and convertible bonds [3] - The establishment of a "patient capital" system is highlighted, with initiatives to involve industry funds in quality M&A projects and support the cultivation of acquisition targets through angel and seed funds [3] - The plan aims to create a virtuous cycle of "exit-reinvestment" to provide stable, long-term funding for valuable M&A projects, avoiding short-term profit-seeking behaviors [3] Group 3: Connecting with Hong Kong Market - The action plan identifies the connection with the Hong Kong capital market as a key task, supporting enterprises in conducting cross-border mergers and acquisitions through various investment methods [4] - Encouragement for collaboration between Shenzhen and Hong Kong to establish equity investment funds for industrial acquisitions is included [4] - The plan also emphasizes the need for cooperation between Shenzhen Stock Exchange and Hong Kong Stock Exchange to explore interconnected mechanisms for M&A and financing [4][5]

Core Viewpoint - The article discusses the "Shenzhen Action Plan for Promoting High-Quality Development of Mergers and Acquisitions (2025-2027)", which aims to enhance the quality of listed companies and support mergers and acquisitions (M&A) in strategic emerging industries, ultimately boosting Shenzhen's economic competitiveness [1][3]. Group 1: Key Tasks and Goals - The plan outlines ten key tasks to enhance the resource allocation function of M&A, supporting listed companies in injecting quality assets and improving investment value [1]. - By the end of 2027, the goal is to increase the total market capitalization of domestic and foreign listed companies in the region to over 20 trillion yuan, cultivate 20 companies with a market value of over 100 billion yuan, and complete over 200 M&A projects with a total transaction value exceeding 100 billion yuan [1][3]. Group 2: Focus on Strategic Emerging Industries - The plan emphasizes M&A activities in strategic emerging industries such as integrated circuits, artificial intelligence, new energy, and biomedicine, encouraging leading companies to acquire quality assets that enhance the industrial chain and key technology levels [3][4]. - The article highlights that successful M&A in the U.S. tech sector, represented by companies like Amazon and Microsoft, has been crucial for their growth, suggesting a similar path for Shenzhen's emerging industries [3]. Group 3: Quality M&A Practices - The article stresses that high-quality M&A should focus on industrial synergy, strengthening the industrial chain, and facilitating corporate transformation, benefiting both individual companies and the overall capital market [4][6]. - Examples include BYD's acquisition of Jabil Inc.'s mobile electronics business in China, which enhances BYD's market position and product structure, and Luxshare Precision's acquisition of Qorvo's semiconductor assets, which strengthens its vertical integration capabilities [4]. Group 4: Support Measures for M&A - The plan proposes expanding financing channels for M&A, encouraging the use of cash, shares, and various bond instruments, and exploring innovative loan options for technology companies [8][9]. - It also aims to establish a "patient capital" system to support quality M&A projects and promote participation from social capital, including private equity and venture capital funds [9]. Group 5: Cross-Border M&A and Collaboration - The plan emphasizes the importance of connecting Shenzhen with Hong Kong's capital market to facilitate cross-border M&A and resource integration, enhancing the influence of Shenzhen's capital market [10]. - It encourages the Shenzhen Stock Exchange to build a comprehensive service platform for M&A, providing full-cycle support and training for companies [10].

1. Report Industry Investment Rating No information provided in the content. 2. Core View of the Report - Under the disturbance of Sino - US tariffs, risk appetite declined, and the convertible bond market was significantly suppressed. The high - priced technology sector, which performed strongly in the early stage, had a large decline, while low - priced convertible bonds showed strong resilience. The net outflow trend of two convertible bond ETFs has eased. The median convertible bond price is still around 130 yuan, lacking cost - effectiveness. Short - duration may suppress convertible bond valuations, and external risks make the convertible bond structure fragile, with potential short - term correction risks. However, from a "slow - bull" perspective, corrections present opportunities, and attention should be paid to the opportunities of equity - biased convertible bonds with large pullbacks [2][5]. 3. Summary According to Relevant Catalogs 3.1 Weekly View and Outlook - Sino - US tariff disturbances led to a decline in risk appetite, suppressing the convertible bond market. The high - priced technology sector fell significantly, and low - priced convertible bonds were more resistant. The net outflow of two convertible bond ETFs slowed down. The median convertible bond price around 130 yuan lacks cost - effectiveness. Short - duration suppression on valuations is yet to be seen, and external risks make the structure fragile, with short - term correction risks. But corrections are opportunities for equity - biased convertible bonds [2][5]. 3.2 Convertible Bond Valuation - Due to tariff disturbances, the convertible bond market retreated, and the 100 - yuan valuation dropped to around 35%. High - rated convertible bonds saw a larger decline in valuations. The overall market's 100 - yuan premium rate was 35.1%, down 0.6% week - on - week, at the 92.8% percentile since 2017. High - rated convertible bonds had weaker valuation performance and a larger decline than low - rated ones [6]. - Compared with last week, the conversion premium rate and bottom - support premium rate in each parity range decreased overall. The 60 - 70 yuan, 100 - 110 yuan, and 120 - 130 yuan parity ranges had larger valuation declines, and the historical quantiles of the conversion premium rate in the 120 - 130 yuan and 130 - 140 yuan parity ranges were significantly low [4][10]. - The median convertible bond price was 129.73 yuan, down 2.64 yuan from last week, and the yield to maturity was - 5.81%, up 0.01%. They are at the 97.50 and 1.70 percentiles since 2017 respectively [4][12]. 3.3 Clause Tracking 3.3.1 Redemption - Five convertible bonds, including New Tai Convertible Bond, Chenfeng Convertible Bond, etc., issued early redemption announcements this week. There are 22 convertible bonds that have issued forced redemption or maturity redemption announcements but have not delisted, with a potential conversion or maturity balance of 14.7 billion yuan. Five convertible bonds announced non - redemption, and the forced redemption ratio this week was 50%. There are currently 34 convertible bonds in the redemption process, and 6 are expected to meet the redemption conditions next week [4][15][18]. 3.3.2 Downward Revision - One convertible bond announced a downward revision result, reaching the bottom. As of now, 112 convertible bonds are in the non - downward - revision range, 23 cannot be downward - revised due to net asset constraints, 1 has triggered the condition but the stock price is still below the trigger price without an announcement, and 33 are accumulating downward - revision days. No convertible bond has issued a downward - revision board plan but not held a general meeting of shareholders [21]. 3.3.3 Put Option - Taiping Convertible Bond issued a conditional put option announcement this week. As of now, 5 convertible bonds are accumulating put - option trigger days, including 1 that has triggered the downward - revision condition, 2 are accumulating downward - revision days, and 2 are in the non - downward - revision range [24]. 3.4 Primary Issuance - Jinlang Convertible Bond 02 was issued this week. Jin 25 Convertible Bond, Yingliu Convertible Bond, Funeng Convertible Bond, and Jinlang Convertible Bond 02 have been issued but not listed. Yingliu Convertible Bond will be listed on October 22, 2025. As of now, there are 5 convertible bonds at the approval - registration stage with a to - be - issued scale of 5 billion yuan, and 6 at the listing - committee - approved stage with a to - be - issued scale of 4 billion yuan [4][27].